In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Drafts Plan To Publicize 'Emerging Signals' Of Device Risks

This article was originally published in The Gray Sheet

Executive Summary

In a draft guidance, FDA explains how it plans to communicate signs of postmarket device risks before it has performed a full analysis or developed specific recommendations. Public health advocates say it is a positive move to get ahead of potential safety problems early. The agency is seeking comment from companies on whether it needs to consult with firms prior to releasing information on emerging signals about their devices.

You may also be interested in...



Firms Must Submit The Good, Bad, And Ugly Trial Data On Devices Under Clinical Trials Rule

Device firms will have to submit a lot more clinical trials outcomes data to the ClinicalTrials.gov portal – including for products that have not been cleared, approved, or launched – based on a final rule recently issued by HHS. Even though sponsors can delay reporting two years, the rule expands the volume of reports that will find their way to the public-facing, clinical trials website, and the change could have downsides, attorneys say.

NSF International Names Former FDA Deputy Director As Executive VP

Regulatory compliance consulting firm NSF International recently appointed Heather Howell, a former deputy director for communications within US FDA’s device center, to serve as executive VP of training and internal quality management systems for the firm’s medical device group in DC.

Consumers Groups Praise FDA Draft ‘Emerging Signals’ Plan; Industry Continues Opposition

FDA’s proposed decision to start giving the public early warning of device risks in its “Emerging Signals” draft was praised by consumer and patient groups in March comments, but industry complained that the agency has no authority to issue early warnings. Companies say the communications will confuse patients and gives firms no chance to review the message FDA sends out about product risks.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT034557

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel